GlassScriptPhysician profile
Robert J Lobonc
NPI 1518941145
$2,283.97
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $389 · 2021: $710 · 2022: $682.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $967.24 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $435.20 | 2021-2022 | |
| Tris Pharma INC | $238.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $146.89 | 2019-2021 | |
| Sobi, INC | $90.18 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $79.82 | 2019-2022 | |
| Pfizer INC. | $73.22 | 2021-2022 | |
| Adlon Therapeutics L.P. | $71.80 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $53.38 | 2021-2022 | |
| Corium, LLC | $45.07 | 2021-2022 | |
| Sanofi Pasteur INC. | $29.74 | 2019-2020 | |
| Aytu Biopharma, INC. | $26.87 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $25.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lobonc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.